Osteopenia and Fosamax, Part 2

There's a follow-up to my earlier post on osteopenia and Merck's Fosamax:

Dr. Harriet Hall (the SkepDoc) has written an analysis of the NPR story with additional medical links.

She charitably allows that Merck may have been more overzealous than greedy, but still comes down in favor of trying non-drug interventions for women under 65.